Avestin EmulsiFlex-C3 High-Pressure Homogenizer
| Brand | AVESTIN |
|---|---|
| Origin | Canada |
| Model | EmulsiFlex-C3 |
| Instrument Type | High-Pressure Homogenizer |
| Dimensions (W×D×H) | 530 × 460 × 760 mm |
| Processing Volume Range | 7–3000 mL |
| Maximum Operating Pressure | 200 MPa (30,000 psi) |
| Sterilization | Direct Steam-in-Place (SIP) |
| Construction Materials | FDA-compliant 316L stainless steel |
| Compliance | Designed for GMP environments, SIP-capable, seal-free fluid path |
Overview
The AVESTIN EmulsiFlex-C3 High-Pressure Homogenizer is an engineered solution for scalable, reproducible nano-scale particle size reduction and cell disruption under strictly controlled process conditions. Based on the principle of high-pressure microfluidization—where sample suspension is forced through a precisely engineered interaction chamber at pressures up to 200 MPa—the system induces intense shear, cavitation, and impact forces that efficiently lyse biological cells or homogenize colloidal dispersions. Unlike rotor-stator or ultrasonic methods, this hydrodynamic mechanism delivers consistent sub-100 nm particle size distributions without introducing metal contamination or thermal degradation, making it especially suitable for sensitive biopharmaceutical actives, liposomal formulations, and nanocrystalline suspensions. The EmulsiFlex-C3 operates across a broad volume range—from 7 mL minimum batch size for early-stage formulation screening to 3 L per hour in continuous mode—enabling seamless transition from discovery to pilot-scale process development.
Key Features
- Patented seal-free fluid path design eliminates elastomeric O-rings and gaskets from all product-contact surfaces, removing a primary source of extractables, leachables, and cross-contamination.
- Integrated steam-in-place (SIP) capability enables full-cycle sterilization at 121 °C without disassembly—validated for repeated cycles in accordance with ISO 13485 and FDA 21 CFR Part 11 requirements for electronic audit trails.
- Modular interaction chamber architecture supports rapid interchange between standard, high-shear, and low-volume configurations—optimized for applications ranging from bacterial lysis to lipid nanoparticle (LNP) formation.
- Robust 316L stainless-steel wetted parts certified to USP Class VI and FDA 21 CFR 178.3570 for food-contact and pharmaceutical use; surface finish Ra ≤ 0.4 µm per ASME BPE-2022 standards.
- Real-time pressure monitoring with dual redundant transducers and programmable ramp/hold profiles ensure compliance with ICH Q5A and Q5C guidelines for bioprocess consistency.
Sample Compatibility & Compliance
The EmulsiFlex-C3 accommodates aqueous buffers, organic-aqueous mixtures, viscous polymer solutions (up to 10,000 cP), and temperature-sensitive biologics—including monoclonal antibodies, mRNA-LNPs, and viral vectors—without compromising structural integrity. Its closed-loop processing path meets containment requirements for BSL-2 agents per CDC/NIH guidelines. All material certifications—including EN 10204 3.1 mill test reports, FDA Drug Master File (DMF) cross-references, and EU Annex 1 alignment documentation—are supplied with each unit. The system is routinely deployed in facilities operating under cGMP, GLP, and ISO 9001 quality management systems, and supports 21 CFR Part 11-compliant electronic signatures when integrated with validated LIMS or SCADA platforms.
Software & Data Management
The EmulsiFlex-C3 operates via a CE-marked, touchscreen HMI running deterministic real-time firmware. Process parameters—including pressure setpoint, flow rate, total processed volume, cycle count, and SIP temperature/time logs—are recorded with timestamped, tamper-evident binary files compliant with ALCOA+ data integrity principles. Optional Ethernet/IP or Modbus TCP connectivity allows integration into MES environments for automated batch record generation. Audit trail functionality includes user login/logout events, parameter change history, and alarm acknowledgments—all retained for ≥30 years per internal retention policy aligned with FDA guidance on electronic records.
Applications
- Cell lysis of E. coli, yeast, mammalian, and insect cells for recombinant protein recovery
- Manufacture of sterile liposomal doxorubicin, amphotericin B, and siRNA delivery systems
- Nanocrystal production of poorly water-soluble APIs (e.g., fenofibrate, itraconazole) per USP
- Preparation of uniform polymeric nanoparticles and exosome-mimetic vesicles
- Stabilization of oil-in-water and water-in-oil emulsions for topical and parenteral dosage forms
- Disaggregation of amyloid fibrils and protein aggregates in neurodegenerative disease research
FAQ
What is the minimum sample volume required for method development?
The EmulsiFlex-C3 achieves reliable homogenization down to 7 mL using its low-volume interaction chamber—ideal for high-value compounds where material conservation is critical.
Can the system be validated for GMP manufacturing?
Yes. Full IQ/OQ/PQ protocols, DQ templates, and risk assessments (per ISO 14971) are available. The SIP cycle is thermally mapped and holds validation for 30+ consecutive cycles.
Is remote operation supported?
Local HMI control is standard; remote monitoring and limited parameter adjustment are possible via secure VPN-connected industrial gateways—subject to site-specific cybersecurity policies.
How does the seal-free design affect maintenance intervals?
Elimination of elastomeric seals reduces scheduled maintenance by ~65% versus conventional homogenizers; only routine calibration of pressure transducers and chamber inspection every 500 operating hours is recommended.
Does AVESTIN provide application support for novel formulations?
Yes. AVESTIN’s global Application Science Team offers protocol optimization, particle sizing correlation studies (with Malvern Mastersizer or Zetasizer), and regulatory dossier support for submissions to Health Canada, EMA, and FDA.
